Kiniksa Pharmaceuticals reported third quarter 2024 ARCALYST net product revenue of $112.2 million. This figure represents a 73% increase compared to the same period in the prior year, demonstrating robust commercial performance for the company's lead product.
Based on this strong performance, Kiniksa raised its expected full-year 2024 ARCALYST net product revenue guidance to a range of $410 million to $420 million. The company also stated its expectation to remain cash flow positive on an annual basis.
In an effort to increase disease awareness, Kiniksa launched the Life DisRPted™ campaign for recurrent pericarditis, partnering with NHL Hall-of-Famer Henrik Lundqvist and GRAMMY® Award-winning singer-songwriter Carly Pearce. The company also confirmed that its Phase 2b clinical trial of abiprubart in Sjögren’s Disease is actively enrolling and dosing patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.